Merck ( NYSE: MRK ) announced that Health Canada has granted approval of Keytruda, in combination with enfortumab vedotin, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer with no prior systemic therapy. This approval is based on the results from the Phase 3 KEYNOTE-A39 trial, which demonstrated statistically significant improvements in overall survival and progression-free survival versus platinum-based chemotherapy. Source: Press Release More on Merck Merck: Buy This Bargain Before It's Gone Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins Merck & Co.
, Inc. (MRK) Q2 2024 Earnings Call Transcript FTC says FDA biosimilar guidance would increase competition, lead to lower prices U.S.
announces final drug prices after Medicare negotiations.
